Treatment of murine Candida krusei or Candida glabrata infection with L- 743,872

J. R. Graybill, R. Bocanegra, M. Luther, A. Fothergill, M. J. Rinaldi

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

L-743,872 is a broad-spectrum pneumocandin antifungal drug developed by Merck Research Co., and in the present work it was evaluated in vivo in murine models of Candida krusei and Candida glabrata infection. Mice were infected intravenously with two isolates of C. krusei and treated with fluconazole or L-743,872. Fluconazole was beneficial only in immune-competent mice infected with isolate 94-2696. At >0.5 mg/kg of body weight/day, L- 743,872 was effective against both infecting isolates in immune-competent and immune-suppressed mice. Against C. glabrata, L-743,872 was effective, at doses ≤0.5 mg/kg, in reducing fungal cell counts in the kidneys but not in the spleen. L-743,872 has significant potential for clinical development.

Original languageEnglish (US)
Pages (from-to)1937-1939
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume41
Issue number9
DOIs
StatePublished - Sep 1997

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Treatment of murine Candida krusei or Candida glabrata infection with L- 743,872'. Together they form a unique fingerprint.

Cite this